209 related articles for article (PubMed ID: 10828880)
1. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells.
Firon M; Shaharabany M; Altstock RT; Horev J; Abramovici A; Resau JH; Vande Woude GF; Tsarfaty I
Oncogene; 2000 May; 19(20):2386-97. PubMed ID: 10828880
[TBL] [Abstract][Full Text] [Related]
2. HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice.
Weimar IS; Weijer K; van den Berk PC; Muller EJ; Miranda N; Bakker AQ; Heemskerk MH; Hekman A; de Gast GC; Gerritsen WR
Br J Cancer; 1999 Sep; 81(1):43-53. PubMed ID: 10487611
[TBL] [Abstract][Full Text] [Related]
3. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
MacDougall CA; Vargas M; Soares CR; Holzer RG; Ide AE; Jorcyk CL
Prostate; 2005 Jul; 64(2):139-48. PubMed ID: 15678502
[TBL] [Abstract][Full Text] [Related]
4. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
5. In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors.
Shaharabany M; Abramovitch R; Kushnir T; Tsarfaty G; Ravid-Megido M; Horev J; Ron R; Itzchak Y; Tsarfaty I
Cancer Res; 2001 Jun; 61(12):4873-8. PubMed ID: 11406565
[TBL] [Abstract][Full Text] [Related]
6. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells.
Jeffers M; Rong S; Anver M; Vande Woude GF
Oncogene; 1996 Aug; 13(4):853-6. PubMed ID: 8761307
[TBL] [Abstract][Full Text] [Related]
7. Mimp, a mitochondrial carrier homologue, inhibits Met-HGF/SF-induced scattering and tumorigenicity by altering Met-HGF/SF signaling pathways.
Leibowitz-Amit R; Tsarfaty G; Abargil Y; Yerushalmi GM; Horev J; Tsarfaty I
Cancer Res; 2006 Sep; 66(17):8687-97. PubMed ID: 16951184
[TBL] [Abstract][Full Text] [Related]
8. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
[TBL] [Abstract][Full Text] [Related]
9. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
[TBL] [Abstract][Full Text] [Related]
10. Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model.
Yu Y; Merlino G
Cancer Res; 2002 May; 62(10):2951-6. PubMed ID: 12019177
[TBL] [Abstract][Full Text] [Related]
11. Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity.
Liang H; O'Reilly S; Liu Y; Abounader R; Laterra J; Maher VM; McCormick JJ
Int J Oncol; 2004 May; 24(5):1057-67. PubMed ID: 15067326
[TBL] [Abstract][Full Text] [Related]
12. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo.
Long IS; Han K; Li M; Shirasawa S; Sasazuki T; Johnston M; Tsao MS
Mol Cancer Res; 2003 Mar; 1(5):393-401. PubMed ID: 12651912
[TBL] [Abstract][Full Text] [Related]
13. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.
Watanabe T; Tsuda M; Makino Y; Ichihara S; Sawa H; Minami A; Mochizuki N; Nagashima K; Tanaka S
Mol Cancer Res; 2006 Jul; 4(7):499-510. PubMed ID: 16849525
[TBL] [Abstract][Full Text] [Related]
14. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
Martens T; Schmidt NO; Eckerich C; Fillbrandt R; Merchant M; Schwall R; Westphal M; Lamszus K
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6144-52. PubMed ID: 17062691
[TBL] [Abstract][Full Text] [Related]
15. [Influence of scatter factor/hepatocyte growth factor on the growth and transmission of hepatocarcinoma SMMC 7721 cells].
Xie Q; Liu K; Hu M; Wu X; Zhou K
Zhonghua Gan Zang Bing Za Zhi; 2001 Apr; 9(2):95-7. PubMed ID: 11350688
[TBL] [Abstract][Full Text] [Related]
16. Met and hepatocyte growth factor/scatter factor expression in human gliomas.
Koochekpour S; Jeffers M; Rulong S; Taylor G; Klineberg E; Hudson EA; Resau JH; Vande Woude GF
Cancer Res; 1997 Dec; 57(23):5391-8. PubMed ID: 9393765
[TBL] [Abstract][Full Text] [Related]
17. Met expression and sarcoma tumorigenicity.
Rong S; Jeffers M; Resau JH; Tsarfaty I; Oskarsson M; Vande Woude GF
Cancer Res; 1993 Nov; 53(22):5355-60. PubMed ID: 7693339
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
19. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase.
Furge KA; Kiewlich D; Le P; Vo MN; Faure M; Howlett AR; Lipson KE; Vande Woude GF; Webb CP
Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10722-7. PubMed ID: 11535809
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor stimulates cell motility in cultures of the striatal progenitor cells ST14A.
Cacci E; Salani M; Anastasi S; Perroteau I; Poiana G; Biagioni S; Augusti-Tocco G
J Neurosci Res; 2003 Dec; 74(5):760-8. PubMed ID: 14635227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
